68CE8E02-F24A-4580-9881-DFBB288E2ED7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 57.88436268068331
- age_years
- 62
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.469
- NOTCH_SIGNALING+0.452
- MYC_TARGETS_V1+0.432
- TGF_BETA_SIGNALING+0.405
- UNFOLDED_PROTEIN_RESPONSE+0.371
- MYC_TARGETS_V2+0.361
- MITOTIC_SPINDLE+0.341
- HEDGEHOG_SIGNALING+0.333
- G2M_CHECKPOINT+0.308
- DNA_REPAIR+0.302
Top 10 suppressed
- MYOGENESIS-0.353
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.347
- ANGIOGENESIS-0.336
- COAGULATION-0.301
- KRAS_SIGNALING_DN-0.295
- SPERMATOGENESIS-0.244
- INTERFERON_GAMMA_RESPONSE-0.235
- INTERFERON_ALPHA_RESPONSE-0.201
- APICAL_SURFACE-0.182
- ALLOGRAFT_REJECTION-0.153
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DE406E2B-39AF-4A24-B2BE-0F7CDCBE9D85 | — | — | 0.923 |
| 2 | 63204446-7AA0-40DC-996D-440F4E19AD0F | — | — | 0.901 |
| 3 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.895 |
| 4 | CD628EE7-84DE-4D82-840B-73718D006B6F | — | — | 0.894 |
| 5 | 4A4E96B0-5AC6-4B7D-AB1C-F814C338589C | — | — | 0.889 |
| 6 | SRR934777 | — | — | 0.888 |
| 7 | 4D9EF242-9F58-4681-ADCF-556E05932931 | — | — | 0.888 |
| 8 | 7779D220-647F-4D6C-890B-022208B51F57 | — | — | 0.888 |
| 9 | SRR934724 | — | — | 0.885 |
| 10 | SRR934791 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.469 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.452 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.432 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.405 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.371 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.361 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.341 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.333 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.308 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.302 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.291 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.282 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.273 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.243 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.233 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.215 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.211 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.188 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.172 | Idelalisib | — uncovered |
| PEROXISOME | 0.166 | Idelalisib | — uncovered |